Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPC

Video

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer (mCRPC).

At the 2020 Genitourinary Cancers Symposium, findings from cohort 4 (n = 81) and cohort 5 (n = 45) of the KEYNOTE-199 trial were presented. In both cohorts, patients with enzalutamide (Xtandi)-resistant mCRPC received the combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi). Notably, cohort 4 consisted of patients with measurable RECIST mCRPC, whereas cohort 5 enrolled patients with nonmeasurable RECIST bone-only/bone-predominant mCRPC.

A 12% overall response rate defined as ≥30% reduction in tumor size was reported in cohort 4. The disease-control rate (DCR) was 51%, and the duration of response was 6.3 months. The DCR in cohort 5 was 51%.

Radiographic progression-free survival was 4.2 months in cohort 4 and 4.4 months in cohort 5. Overall survival was not reached in cohort 4 and was 18.8 months in cohort 5.

Overall, 40% of patients had a prostate-specific antigen (PSA) decline from baseline. Notably, 14% of patients experienced a PSA decline ≥50%.

The combination is currently being evaluated in the phase III KEYNOTE-641 trial.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,